Asserachrom free tfpi

Manufactured by Diagnostica Stago

Sourced in France

The Asserachrom® Free TFPI is a lab equipment product that measures the levels of Free Tissue Factor Pathway Inhibitor (TFPI) in human plasma samples. It is a quantitative assay used for in vitro diagnostic purposes.

Automatically generated - may contain errors

Lab products found in correlation

Sta r analyzer, by Diagnostica Stago (1 mentions) Soluble p selectin, by R&D Systems (1 mentions) Ppp reagent low, by Diagnostica Stago (1 mentions) Sta liatest d di, by Diagnostica Stago (1 mentions) Bovine calf serum (bcs), by Siemens (1 mentions) Asserachrom vwf ag, by Diagnostica Stago (1 mentions) Qiaamp ultrasens virus kit, by Qiagen (1 mentions) Dade thrombin reagent, by Siemens (1 mentions) Fluoroscan ascent fluorometer, by Thermo Fisher Scientific (1 mentions) Asserachrom d dimer, by Diagnostica Stago (1 mentions) Asserachrom d di, by Diagnostica Stago (1 mentions) Sta r evolution analyzer, by Diagnostica Stago (1 mentions)

6 protocols using asserachrom free tfpi

Coagulation and Inflammatory Biomarkers Measurement

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fibrinogen (Dade^® Thrombin reagent, Siemens, Marburg, Germany) and coagulation factor VIII (TriniCLOT automated aPTT, Diagnostica Stago, Asnières, France) were determined by chronometric coagulation assays on BCS (Dade Behring, Deerfield, IL, USA). D-dimer levels were measured by quantitative latex assay (STA-Liatest D-Di^®, Diagnostica Stago) on a STA-R analyzer (Diagnostica Stago). Soluble P-selectin (R&D Systems, Minneapolis, MN, USA), interleukin-6 (R&D Systems), von Willebrand factor antigen (Asserachrom^® VWF:Ag, Diagnostica Stago) and free TFPI (Asserachrom^® Free TFPI, Diagnostica Stago) were measured by immunoassay following the manufacturer’s instructions. Circulating extracellular DNA was extracted from plasma samples using QIAamp^® UltraSens Virus Kit (Qiagen) and measured using the PicoGreen Quant-iT dsDNA Assay Kit (Life Technologies). The measurement of MV-TF activity was performed according to standardized protocol for a chromogenic endpoint assay measuring TF-dependent Xa generation as reported previously [36 (link)]. Plasma thrombin generation was measured in PFP using the Calibrated Automated Thrombogram (CAT^®, Diagnostica Stago) at a final concentration of 1 pM TF and 4 mM phospholipids (PPP-Reagent LOW^®, Diagnostica Stago).

Faille D., Bourrienne M.C., de Raucourt E., de Chaisemartin L., Granger V., Lacroix R., Panicot-Dubois L., Hammel P., Lévy P., Ruszniewski P., Ajzenberg N, & Rebours V. (2018). Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process. Oncotarget, 9(41), 26453-26465.

+ Open protocol

+ Expand

Coagulation and Fibrinolysis Measurements

Check if the same lab product or an alternative is used in the 5 most similar protocols

Thrombin formation in cryopreserved citrate plasma was assayed using the CAT assay [36 (link)] according to the user manual provided by Thrombinoscope B.V (Maastricht, The Netherlands). From the CAT assay we analyzed the parameters ETP, ie. the area under the thrombin generation curve and Peak, the maximum concentration of thrombin. Coagulation was triggered by recalcification of plasma in the presence of 5 pM recombinant, relipidated human tissue factor (PPP-reagent, Thrombinoscope B.V), and 417 μM fluorogenic substrate (FluCa, Thrombinoscope B.V). Fluorescence was monitored using the Fluoroscan Ascent fluorometer (ThermoLabsystems, Helsinki, Finland), and the thrombin generation parameters were calculated using the Thrombinoscope® software (Thrombino-scope B.V). In order to increase reproducibility all CAT-derived parameters were normalized by dividing the measured test value with that of reference plasma pooled from 34 healthy adults run in the same assay.
Free protein S, free Tissue Factor Plasminogen Inhibitor (TFPI) and D-dimer were analyzed in cryopreserved citrate plasma using commercial ELISA kits (Zymutest free protein S from Hyphen Biomed, Neuville Sur Oise, France; Asserachrom® Free TFPI and Asserachrom® D-Dimer from Diagnostica Stago, Asnières, France).

Prebensen C., Trøseid M., Ueland T., Dahm A., Sandset P.M., Aaberge I., Waalen K., Dyrhol-Riise A.M., Taskén K, & Kvale D. (2017). Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial. PLoS ONE, 12(5), e0176527.

+ Open protocol

+ Expand

Plasma TFPI Levels in CLL Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols

Citrated venous blood samples were collected from 36 CLL patients (25 males and 11 females, mean age 65 years, range 38–80 years). Patients were also clinically staged according to the Binet staging system^{26 (link),27 (link)} with the following distribution: stage A, 21 (58.3%), stage B, 7 (19.4%) and stage C, 8 (22.2%). Citrated venous blood samples from 34 healthy subjects (17 males and 17 females, mean age 42 years, range 24–68 years) were used as controls. Plasma samples were collected by centrifugation at 2500×g for 15 min at 20 °C. Plasma aliquots were frozen and stored at − 80 °C until being assayed. The commercial enzyme-linked immunosorbent assay (ELISA) Asserachrom Free TFPI (Diagnostica Stago, Asnières, France) was used to measure the concentration of full-length TFPI in the plasma according to the manufacturer’s protocol^{28 (link)}.

Cui X.Y., Tjønnfjord G.E., Kanse S.M., Dahm A.E., Iversen N., Myklebust C.F., Sun L., Jiang Z.X., Ueland T., Campbell J.J., Ho M, & Sandset P.M. (2021). Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia. Scientific Reports, 11, 5127.

+ Open protocol

+ Expand

Endogenous Thrombin Potential Measurement

Check if the same lab product or an alternative is used in the 5 most similar protocols

The endogenous thrombin potential (ETP) was measured using the Calibrated Automated Thrombogram (CAT) assay
[26 (link)], according to the manufacturer’s instructions (Thrombinoscope B.V, Maastricht, the Netherlands). Four thrombin generation parameters were recorded; ETP (time integral of the thrombin formation), lag time, peak thrombin (Peak), and time to peak thrombin (ttPeak). APC resistance was determined after the addition of APC (American Diagnostica Inc., Stamford, CT, USA), and the results were reported as APC-sensitivity ratio (APC-sr); which is the ratio of ETP in presence of APC divided by ETP in absence of APC normalized against the similar ratio obtained with PNP measured in the same run
[25 (link)]. The coagulation inhibitors antithrombin and protein C activities, and free protein S antigen, were analyzed using the Chromogenix Coamatic® Antithrombin, the Chromogenix Coamatic® Protein C, and the Chromogenix Coamatic® Protein S-Free kits from Instrumentation Laboratory (Lexington, MA, USA). Free TFPI antigen and D-dimer were analyzed by the commercial enzyme-linked immunosorbent assay kits Asserachrom® Free TFPI and Asserachrom® D-DI from Diagnostica Stago, Asnières, France. The hemostatic parameters are shown in Additional file
1: Figure S1.

Tinholt M., Viken M.K., Dahm A.E., Vollan H.K., Sahlberg K.K., Garred Ø., Børresen-Dale A.L., Jacobsen A.F., Kristensen V., Bukholm I., Kåresen R., Schlichting E., Skretting G., Lie B.A., Sandset P.M, & Iversen N. (2014). Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study. BMC Cancer, 14, 845.

+ Open protocol

+ Expand

Coagulation and Fibrinolysis Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols

PT, APTT, and CFIB were measured using STA Neoplastine C1 plus, STA Cephascreen, and STA fibrinogen in clot-based assays, respectively. Antithrombin (AT), protein C (PC), free protein S (FPS), and DD were assayed using STA-Stachrom ATIII, STA-Stachrom protein C, Liatest Free Protein S, and STA Liatest D-Di. Colorimetric technique was employed for AT and PC, while latex immunoassay technology was employed for DD and FPS. FVII and FVIII were assayed using STA deficient VII/VIII immunodepleted plasma in coagulation-based assays. All reagents were purchased from Diagnostica Stago (Asniers, France) with assays performed on STA-R Evolution analyzer (Diagnostica Stago) according to manufacturer protocols and as previously described.
21 (link)
Free tissue factor pathway inhibitor (TFPI) was measured using an ELISA (Asserachrom Free TFPI, Diagnostica Stago). PAI was also measured with ELISA (Human Serpin E1/PAI-1 Quantikine ELISA kit (DSE100), R&D Systems).

Chitongo P.B., Roberts L.N., Yang L., Patel R.K., Lyall R., Luxton R., Aylwin S.J, & Arya R. (2017). Visceral Adiposity Is an Independent Determinant of Hypercoagulability as Measured by Thrombin Generation in Morbid Obesity. TH Open: Companion Journal to Thrombosis and Haemostasis, 1(2), e146-e154.

+ Open protocol

+ Expand

Quantifying Free TFPI Antigen

Check if the same lab product or an alternative is used in the 5 most similar protocols

Free tissue factor pathway inhibitor antigen (TFPI) was assayed with Asserachrom Free TFPI (Diagnostica Stago). Most of the TFPI is bound to endothelial cells, but it is also found in platelets and is released on activation. TFPI in plasma is found in the following 2 forms: lipoprotein-associated (approximately 80%) and free TFPI. Only the free form of TFPI is associated with the anticoagulant activity. The normal level of TFPI is 10 ng/mL.

Garabet L., Eriksson A., Tjønnfjord E., Cui X.Y., Olsen M.K., Jacobsen H.K., Jørgensen C.T., Mathisen Å.B., Mowinckel M.C., Ahlen M.T., Sørvoll I.H., Horvei K.D., Ernstsen S.L., Lægreid I.J., Stavik B., Holst R., Sandset P.M, & Ghanima W. (2022). SARS-CoV-2 vaccines are not associated with hypercoagulability in apparently healthy people. Research and Practice in Thrombosis and Haemostasis, 7(1), 100002.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!